Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC

Dr Mark Kris discusses neoadjuvant approaches for patients non-small cell lung cancer with oncogenic drivers for which there are effective targeted therapies.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news